Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Diagnosis of Alzheimer's disease using plasma biomarkers adjusted to clinical probability

  • Therriault, J.
  • Janelidze, S.
  • Benedet, A.L.
  • Ashton, Nicholas J.|||0000-0002-3579-8804
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Gonzalez-Escalante, A.
  • Bellaver, B.|||0000-0002-2212-3373
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Vrillon, A.
  • Karim, H.
  • Mielke, M.M.
  • Hyung Hong, C.
  • Roh, H.W.
  • Contador, José
  • Puig Pijoan, A.
  • Algeciras-Schimnich, A.
  • Vemuri, P.|||0000-0003-4286-0589
  • Graff-Radford, J.
  • Lowe, V.J.
  • Karikari, Thomas K.|||0000-0003-1422-4358
  • Jonaitis, E.
  • Brum, W.
  • Tissot, C.
  • Servaes, S.
  • Rahmouni, N.
  • Macedo, A.C.
  • Stevenson, J.
  • Fernandez-Arias, J.
  • Wang, Y.T.
  • Woo, M.S.
  • Friese, M.A.|||0000-0001-6380-2420
  • Jia, W.L.
  • Dumurgier, J.
  • Hourregue, C.
  • Cognat, E.
  • Ferreira, P.L.
  • Vitali, P.|||0000-0001-8953-1542
  • Johnson, S.
  • Pascoal, Tharick|||0000-0001-9057-8014
  • Gauthier, S.
  • Lleó, Alberto|||0000-0002-2568-5478
  • Paquet, C.
  • Petersen, R.C.
  • Salmon, D.
  • Mattsson-Carlgren, N.
  • Palmqvist, S.
  • Stomrud, E.
  • Galasko, D.
  • Son, S.J.
  • Zetterberg, Henrik|||0000-0003-3930-4354
  • Fortea, Juan|||0000-0002-1340-638X
  • Suárez Calvet, Marc|||0000-0002-2993-569X
  • Jack Jr, Clifford R.|||0000-0001-7916-622X
  • Blennow, Kaj|||0000-0002-1890-4193
  • Hansson, Oskar|||0000-0001-8467-7286
  • Rosa-Neto, P.
Recently approved anti-amyloid immunotherapies for Alzheimer's disease (AD) require evidence of amyloid-β pathology from positron emission tomography (PET) or cerebrospinal fluid (CSF) before initiating treatment. Blood-based biomarkers promise to reduce the need for PET or CSF testing; however, their interpretation at the individual level and the circumstances requiring confirmatory testing are poorly understood. Individual-level interpretation of diagnostic test results requires knowledge of disease prevalence in relation to clinical presentation (clinical pretest probability). Here, in a study of 6,896 individuals evaluated from 11 cohort studies from six countries, we determined the positive and negative predictive value of five plasma biomarkers for amyloid-β pathology in cognitively impaired individuals in relation to clinical pretest probability. We observed that p-tau217 could rule in amyloid-β pathology in individuals with probable AD dementia (positive predictive value above 95%). In mild cognitive impairment, p-tau217 interpretation depended on patient age. Negative p-tau217 results could rule out amyloid-β pathology in individuals with non-AD dementia syndromes (negative predictive value between 90% and 99%). Our findings provide a framework for the individual-level interpretation of plasma biomarkers, suggesting that p-tau217 combined with clinical phenotyping can identify patients where amyloid-β pathology can be ruled in or out without the need for PET or CSF confirmatory testing.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Diagnostic performance of plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL along the continuum of Alzheimer's disease and non-AD dementias, An international multi-center study

  • Doecke, J.D.|||0000-0003-2863-0293
  • Bellomo, G.
  • Vermunt, L.
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Halbgebauer, S.
  • in 't Veld, S.
  • Mattsson-Carlgren, N.
  • Veverova, K.
  • Fowler, C.J.
  • Boonkamp, L.
  • Houtkamp, I.M.
  • Koel-Simmerlink, M.
  • Verberk, I.M.W.
  • Gaetani, L.
  • Toja, A.
  • Wojdała, A.L.
  • Fortea, Juan|||0000-0002-1340-638X
  • Pijnenburg, Y.
  • Lemstra, A.
  • van der Flier, W.
  • Hort, J.
  • Hansson, Oskar|||0000-0001-8467-7286
  • Parnetti, Lucilla|||0000-0001-5722-3967
  • Masters, C.L.
  • Lleó, Alberto|||0000-0002-2568-5478
  • González-Escalante, Armand
  • Contador, José
  • Suárez Calvet, Marc|||0000-0002-2993-569X
  • Fernández-Lebrero, Aida|||0000-0002-2097-4430
  • Puig-Pijoan, Albert|||0000-0002-9848-3711
  • Ortiz-Romero, Paula|||0000-0002-6378-6763
  • Jiménez-Moyano, Esther|||0000-0002-0005-6544
  • Minguillón, Carolina
  • Campo Milán, Marta del|||0000-0003-2808-3699
  • Teunissen, Charlotte E.|||0000-0002-4061-0837
  • Otto, M.|||0000-0003-4273-4267
INTRODUCTION: Plasma phosphorylated tau (p-tau)181, glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), and amyloid beta ratio (Aβ42/40) may have diagnostic and prognostic value in Alzheimer's disease (AD). Here we assess which markers can best identify AD from controls and other non-AD dementias in a large international multi-center study. METHODS: Plasma samples (n = 1298) were collected from six international centers. Aβ40, Aβ42, GFAP, NfL, and p-tau181 were measured using single molecule array. In each group, AD diagnosis/co-pathology was defined according to cerebrospinal fluid biomarkers or amyloid positron emission tomography. Validations were performed in three separate cohorts via single and dual cut-off models. RESULTS: p-tau181 showed the best area under the curve value to separate AD from frontotemporal dementia, controls, and Aβ- dementia with Lewy bodies. However, this discriminative power could not be reproduced by applying pre-defined cut-offs. DISCUSSION: p-tau181 was the best single plasma marker for detecting AD at any stage. Specific cut-offs are needed to maximize diagnostic performances. Highlights: Phosphorylated tau (p-tau)181 provided a clear differentiation between controls and Alzheimer's disease (AD) participants, with evidence of increased levels in the preclinical stage of AD. Plasma biomarkers demonstrated that when amyloid co-pathology is removed from dementia with Lewy bodies (DLB), only glial fibrillary acidic protein and neurofilament light chain remain to predict DLB. Given the low prevalence of amyloid co-pathology in frontotemporal dementia (FTD), p-tau181 and its ratio with amyloid beta 42 are strong biomarkers to differentiate FTD from AD.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Plasma Phosphorylated Tau 217 to Identify Preclinical Alzheimer Disease

  • Janelidze, Shorena
  • Therriault, Joseph
  • Brum, Wagner S.
  • Pichet Binette, Alexa|||0000-0001-5218-3337
  • Stomrud, Erik
  • Palmqvist, Sebastian|||0000-0002-9267-1930
  • Teunissen, Charlotte E.|||0000-0002-4061-0837
  • van der Flier, Wiesje M.|||0000-0001-8766-6224
  • Rahmouni, Nesrine
  • Gispert, Juan Domingo|||0000-0002-6155-0642
  • Blennow, Kaj|||0000-0002-1890-4193
  • Doré, Vincent
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Fortea, Juan|||0000-0002-1340-638X
  • Villeneuve, Sylvia
  • Johnson, Sterling C.
  • Rosa-Neto, Pedro|||0000-0001-9116-1376
  • Petersen, Ronald C.
  • Schindler, Suzanne E.
  • Suárez Calvet, Marc|||0000-0002-2993-569X
  • Ossenkoppele, Rik
  • Hansson, Oskar|||0000-0001-8467-7286
  • Salvadó, Gemma
  • Bali, Divya
  • Orduña Dolado, Anna
  • Mattsson-Carlgren, Niklas
  • Coomans, Emma M.
  • Benzinger, Tammie L. S.
  • Feizpour, Azadeh
  • Rowe, Christopher C.
  • Jack Jr, Clifford R.|||0000-0001-7916-622X
Importance: Advances in Alzheimer disease (AD) have shifted research focus to earlier disease stages, necessitating more scalable approaches to identify cognitively unimpaired individuals with amyloid β (Aβ) pathology. Objective: To assess the utility of plasma phosphorylated tau 217 (p-tau217) for classifying Aβ status in cognitively unimpaired individuals, both as a stand-alone test and in a 2-step approach where positive plasma results were confirmed using a second modality (Aβ positron emission tomography [PET] or cerebrospinal fluid [CSF]). Design, Setting, and Participants: This cross-sectional cohort study used data collected between June 2009 and March 2024. We included 2916 cognitively unimpaired participants from 12 international independent observational cohorts in the US, Europe, Australia, and Canada with available plasma p-tau217 levels and CSF or PET Aβ biomarkers. Performance comparisons between mass spectrometry and immunoassay-based p-tau217 measurements were also performed (n = 964). Exposures: Plasma p-tau217 levels measured by immunoassay. Main Outcome and Measures: Aβ status, determined by CSF or Aβ PET biomarkers. Results: Participants had a mean (SD) age of 66.9 (9.9) years; 971 (33.3%) were Aβ positive by either CSF or PET, 1667 (57.2%) were women, and 1108 (38.1%) carried at least 1 APOE ϵ4 allele. As a stand-alone test, plasma p-tau217 achieved a positive predictive value (PPV) of 79% (95% CI, 74-84) and an overall accuracy of 81% (95% CI, 80-82). In a 2-step workflow, the PPV and accuracy significantly increased to 91% (95% CI, 86-95). While this approach required screening of 677 individuals with plasma p-tau217 to identify 100 Aβ-positive individuals, compared to 536 participants when using PET alone, it reduced the need for PET testing to 124. Immunoassays demonstrated comparable PPVs to mass spectrometry (80% [95% CI, 74-86] vs 85% [95% CI, 81-90]; P =.12) but significantly lower overall accuracy (82% [95% CI, 79-84]% vs 88 [95% CI, 86-90]; P <.001) and true Aβ-positive detection rate (49% [95% CI, 43-55] vs 69% [95% CI, 64-75]; P <.001). Conclusions and Relevance: The findings highlight the potential of plasma p-tau217 as a stand-alone test - or when used in a sequential 2-step approach alongside PET or CSF testing - as a cost-effective, scalable, and minimally burdensome strategy for identifying preclinical AD. Tailored screening workflows that incorporate p-tau217 can improve efficiency in participant selection for preclinical AD trials and, in the future, help guide access to disease-modifying treatments..
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Genetically predicted telomere length and Alzheimer’s disease endophenotypes: a Mendelian randomization study

  • Rodríguez-Fernández, Blanca
  • Vilor-Tejedor, Natalia
  • Arenaza-Urquijo, Eider M.
  • Sánchez-Benavides, Gonzalo
  • Suárez-Calvet, Marc
  • Operto, Grégory
  • Minguillón, Carolina
  • Fauria, Karine
  • Kollmorgen, Gwendlyn
  • Suridjan, Ivonne
  • Castro de Moura, Manuel
  • Piñeyro, David
  • Esteller, Manel
  • Blennow, Kaj
  • Zetterberg, Henrik
  • De Vivo, Immaculata
  • Molinuevo, José Luis
  • Navarro, Arcadi
  • Gispert, Juan Domingo
  • Sala-Vila, Aleix
  • Crous-Bou, Marta
  • ALFA study
Telomere length (TL) is associated with biological aging, consequently influencing the risk of age-related diseases such as Alzheimer’s disease (AD). We aimed to evaluate the potential causal role of TL in AD endophenotypes (i.e., cognitive performance, N = 2233; brain age and AD-related signatures, N = 1134; and cerebrospinal fluid biomarkers (CSF) of AD and neurodegeneration, N = 304) through a Mendelian randomization (MR) analysis. Our analysis was conducted in the context of the ALFA (ALzheimer and FAmilies) study, a population of cognitively healthy individuals at risk of AD. A total of 20 single nucleotide polymorphisms associated with TL were used to determine the effect of TL on AD endophenotypes. Analyses were adjusted by age, sex, and years of education. Stratified analyses by APOE-ɛ4 status and polygenic risk score of AD were conducted. MR analysis revealed significant associations between genetically predicted longer TL and lower levels of CSF Aβ and higher levels of CSF NfL only in APOE-ɛ4 non-carriers. Moreover, inheriting longer TL was associated with greater cortical thickness in age and AD-related brain signatures and lower levels of CSF p-tau among individuals at a high genetic predisposition to AD. Further observational analyses are warranted to better understand these associations., The project leading to these results has received funding from the Alzheimer’s Association (Grant AARG-19-618265). This project has received funding from Instituto de Salud Carlos III (PI19/00119). Additional support has been received from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004, the Alzheimer’s Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007), the Health Department of the Catalan Government (Health Research and Innovation Strategic Plan (PERIS) 2016-2020 grant# SLT002/16/00201), and the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant no. 2017-SGR-892. All CRG authors acknowledge the support of the Spanish Ministry of Science, Innovation and Universities to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Programme/Generalitat de Catalunya. NV-T is funded by a post-doctoral grant, Juan de la Cierva Incorporación Programme (IJC2020-043216-I), Ministry of Science and Innovation–Spanish State Research Agency. EMAU is supported by the Spanish Ministry of Science, Innovation and Universities - Spanish State Research Agency (RYC2018-026053-I). MS-C receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (Grant agreement no. 948677). MS-C also receives funding from the Instituto de Salud Carlos III (PI19/00155) and from the Spanish Ministry of Science, Innovation and Universities (Juan de la Cierva Programme grant IJC2018-037478-I). HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532); the European Research Council (#681712); Swedish State Support for Clinical Research (#ALFGBG-720931); the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862); the AD Strategic Fund and the Alzheimer’s Association (#ADSF-21-831376-C, #ADSF-21-831381-C, and #ADSF-21-831377-C); the Olav Thon Foundation; the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2019-0228); the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE); and the UK Dementia Research Institute at UCL. KB is supported by the Swedish Research Council (#2017-00915); the Alzheimer Drug Discovery Foundation (ADDF), USA (#RDAPB-201809-2016615); the Swedish Alzheimer Foundation (#AF-742881); Hjärnfonden, Sweden (#FO2017-0243); the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986); the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236); and the National Institute of Health (NIH), USA, (grant #1R01AG068398-01). JDG is supported by the Spanish Ministry of Science and Innovation (RYC-2013-13054). AS-V. is the recipient of an Instituto de Salud Carlos III Miguel Servet II fellowship (CP II 17/00029).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Proteomic polygenic risk scores of age-related plasma protein levels reveal a role for Metalloproteinase inhibitor 2 (TIMP2) in cognitive performance

  • Anastasi, Federica
  • Genius, Patricia
  • Rodriguez-Fernandez, Blanca
  • Yang, Chengran
  • Gorijala, Priyanka
  • Timsina, Jigyasha
  • Hernández-Villamizar, Felipe
  • Lorenzini, Luigi
  • Del Campo, Marta
  • Sánchez-Benavides, Gonzalo
  • Minguillon, Carolina
  • Navarro, Arcadi
  • Cruchaga, Carlos
  • Suárez-Calvet, Marc
  • Vilor-Tejedor, Natalia
Several studies in mice have identified blood proteins that influence brain aging, yet translating these findings into humans remains challenging. To address this gap, we conducted a systematic review that identified 12 proteins reported to have an aging or rejuvenating effect in murine brains. Using protein quantitative trait loci data, we computed proteomic polygenic risk scores (protPRSs) capturing the lifelong genetic predisposition to higher or lower plasma protein levels and their regulation. We first validated the prediction accuracy of these protPRSs in two independent cohorts: 10 protPRSs in the Knight-ADRC and 7 protPRSs in the ALFA+ cohort significantly predicted their corresponding protein levels, although effect sizes were modest. We then examined their association with cognitive performance in cognitively unimpaired individuals at risk of Alzheimer's disease of the ALFA+ cohort. Among the protPRSs tested, the metalloproteinase inhibitor 2 (TIMP2) protPRS was significantly associated with better global cognition and episodic memory. These associations were consistent across stratifications by sex, APOE-ε4, and amyloid-β status, although some did not survive multiple testing corrections. TIMP2 protPRS correlated with measured TIMP2 levels, but actual plasma concentrations were not significantly related to cognition. This finding aligns with murine evidence of TIMP2's brain-rejuvenating role. By leveraging genetic predisposition to protein abundance and regulation, protPRSs may provide complementary insight into long-term biological processes not captured by single protein measurements. Our results support TIMP2 as a candidate for further investigation in the context of brain aging and cognitive decline., The research leading to these results has received funding from “la Caixa” Foundation, under agreement LCF/PR/SC22/68000001, the Health Department of the Catalan Government (Health Research and Innovation Strategic Plan (PERIS) 2016–2020 grant# SLT002/16/00201) and the Alzheimer’s Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17–519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under grant no. 2021 SGR 00913 and 2021 SGR 01137. FA receives funding from the JDC2022–049347-I grant, funded by the MCIU/AEI/10.13039/501100011033 and the European Union NextGenerationEU/PRTR. This work was supported in part by grants from the National Institutes of Health (R01AG044546 (CC), P01AG003991(CC), RF1AG053303 (CC), RF1AG058501 (CC), U01AG058922 (CC), the Chan Zuckerberg Initiative (CZI), the Alzheimer’s Association Zenith Fellows Award (ZEN-22–848604, awarded to CC), and an Anonymous foundation. The recruitment and clinical characterization of research participants at Washington University were supported by NIH P30AG066444 (JCM), P01AG03991(JCM), and P01AG026276(JCM). This work was supported by access to equipment made possible by the Hope Center for Neurological Disorders, the Neurogenomics and Informatics Center (NGI: https://neurogenomics.wustl.edu/)and the Departments of Neurology and Psychiatry at Washington University School of Medicine. MS-C receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (Grant agreement No. 948677); ERA PerMed (ERAPERMED2021–184); Project "PI19/00155" and “PI22/00456, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union; and from a fellowship from ”la Caixa” Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648 (LCF/BQ/PR21/11840004). NV-T was supported by the Spanish Ministry of Science and Innovation - State Research Agency (IJC2020–043216-I/MCIN/AEI/10.13039/501100011033) and the European Union «NextGenerationEU» /PRTR and currently receives funding from the Spanish Research Agency MICIU/AEI/10.13039/501100011033 (grant RYC2022–038136-I cofunded by the European Union FSE+ and grant PID2022–143106OA-I00 cofunded by the European Union FEDER). Additionally, NV-T is supported in part by the William H. Gates Sr. Fellowship from the Alzheimer’s Disease Data Initiative. All CRG authors acknowledge the support of the Spanish Ministry of Science, Innovation, and Universities to the EMBL partnership, the Centro de Excelencia Severo Ochoa, and the CERCA Programme/Generalitat de Catalunya., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Clinical performance and head-to-head comparison of CSF p-tau235 with p-tau181, p-tau217 and p-tau231 in two memory clinic cohorts

  • Lantero Rodríguez, Juan|||0000-0002-7426-678X
  • Vrillon, Agathe
  • Fernández-Lebrero, Aida|||0000-0002-2097-4430
  • Ortiz-Romero, Paula|||0000-0002-6378-6763
  • Snellman, Anniina
  • Montoliu Gaya, Laia|||0000-0001-7684-6318
  • Brum, Wagner S.
  • Cognat, Emmanuel
  • Dumurgier, Julien
  • Puig-Pijoan, Albert|||0000-0002-9848-3711
  • Navalpotro-Gómez, Irene
  • García-Escobar, Greta
  • Karikari, Thomas K.|||0000-0003-1422-4358
  • Vanmechelen, Eugeen|||0000-0002-9466-5366
  • Ashton, Nicholas J.|||0000-0002-3579-8804
  • Zetterberg, Henrik|||0000-0003-3930-4354
  • Suárez Calvet, Marc|||0000-0002-2993-569X
  • Paquet, Claire|||0000-0002-2273-7316
  • Blennow, Kaj|||0000-0002-1890-4193
Cerebrospinal fluid (CSF) p-tau235 is a novel biomarker highly specific of Alzheimer's disease (AD). However, CSF p-tau235 has only been studied in well-characterized research cohorts, which do not fully reflect the patient landscape found in clinical settings. Therefore, in this multicentre study, we investigated the performance of CSF p-tau235 to detect symptomatic AD in clinical settings and compared it with CSF p-tau181, p-tau217 and p-tau231. CSF p-tau235 was measured using an in-house single molecule array (Simoa) assay in two independent memory clinic cohorts: Paris cohort (Lariboisière Fernand-Widal University Hospital Paris, France; n.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease, An international overview

  • Delaby, Constance|||0000-0002-8606-6814
  • Teunissen, Charlotte E.|||0000-0002-4061-0837
  • Blennow, Kaj|||0000-0002-1890-4193
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Arisi, Ivan
  • Amar, Elodie Bouaziz
  • Beaume, Anne
  • Bedel, Aurelie
  • Bellomo, Giovanni|||0000-0003-0456-5650
  • Bigot-Corbel, Edith
  • Bjerke, Maria
  • Blanc-Quintin, Marie-Céline
  • Boada, Mercè|||0000-0003-2617-3009
  • Bousiges, Olivier|||0000-0001-6786-3191
  • Chapman, Miles D.
  • DeMarco, Mari L.
  • D'Onofrio, Mara
  • Dumurgier, Julien
  • Dufour-Rainfray, Diane
  • Engelborghs, Sebastiaan|||0000-0003-0304-9785
  • Esselmann, Hermann
  • Fogli, Anne
  • Gabelle, Audrey
  • Galloni, Elisabetta
  • Gondolf, Clémentine
  • Grandhomme, Frédérique
  • Grau-Rivera, Oriol|||0000-0002-4730-5341
  • Hart, Melanie
  • Ikeuchi, Takeshi|||0000-0001-8828-8085
  • Jeromin, Andreas
  • Kasuga, Kensaku
  • Keshavan, Ashvini
  • Khalil, Michael|||0000-0002-5350-3328
  • Körtvelyessy, Peter
  • Kulczynska-Przybik, Agnieszka
  • Laplanche, Jean-Louis
  • Lewczuk, Piotr|||0000-0002-8101-6535
  • Li, Qiao-Xin
  • Lleó, Alberto|||0000-0002-2568-5478
  • Malaplate, Catherine
  • Marquié, Marta|||0000-0002-0660-0950
  • Masters, Colin L.
  • Mroczko, Barbara
  • Nogueira, Léonor
  • Orellana del Río, Adelina|||0000-0002-0204-1944
  • Otto, Markus
  • Oudart, Jean-Baptiste
  • Paquet, Claire|||0000-0002-2273-7316
  • Paoletti, Federico Paolini
  • Parnetti, Lucilla|||0000-0001-5722-3967
  • Perret-Liaudet, Armand
  • Peoc'h, Katell
  • Poesen, Koen
  • Puig-Pijoan, Albert|||0000-0002-9848-3711
  • Quadrio, Isabelle
  • Quillard-Muraine, Muriel
  • Rucheton, Benoit
  • Schraen, Susanna
  • Schott, Jonathan M.|||0000-0003-2059-024X
  • Shaw, Leslie M.
  • Suárez Calvet, Marc|||0000-0002-2993-569X
  • Tsolaki, Magda|||0000-0002-2072-8010
  • Tumani, Hayrettin|||0000-0002-1647-6201
  • Udeh-Momoh, Chinedu|||0000-0002-7357-4692
  • Vaudran, Lucie
  • Verbeek, Marcel M.
  • Verde, Federico
  • Vermunt, Lisa
  • Vogelgsang, Jonathan|||0000-0001-9326-8193
  • Wiltfang, Jens
  • Zetterberg, Henrik|||0000-0003-3930-4354
  • Lehmann, Sylvain|||0000-0001-6117-562X
The current practice of quantifying cerebrospinal fluid (CSF) biomarkers as an aid in the diagnosis of Alzheimer's disease (AD) varies from center to center. For a same biochemical profile, interpretation and reporting of results may differ, which can lead to misunderstandings and raises questions about the commutability of tests. We obtained a description of (pre-)analytical protocols and sample reports from 40 centers worldwide. A consensus approach allowed us to propose harmonized comments corresponding to the different CSF biomarker profiles observed in patients. The (pre-)analytical procedures were similar between centers. There was considerable heterogeneity in cutoff definitions and report comments. We therefore identified and selected by consensus the most accurate and informative comments regarding the interpretation of CSF biomarkers in the context of AD diagnosis. This is the first time that harmonized reports are proposed across worldwide specialized laboratories involved in the biochemical diagnosis of AD.